FGF21 and metabolic dysfunction-associated steatohepatitis: An extensive body of literature have demonstrated the protective effects of recombinant FGF21 or FGF21 analogues in preclinical models of NASH (284, 285) and atherosclerosis (286, 287) as well as in patients with NASH (288, 289), serving as an attractive therapeutic marker for both diseases.